It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Omicron has become the dominant SARS-CoV-2 variant globally since December 2021, with distinct waves being associated with separate Omicron sublineages. Rapid detection of BA.1, BA.2, BA.4, and BA.5 was accomplished in the province of Alberta, Canada, through the design and implementation of real-time reverse transcriptase PCR assays targeting S:N501Y, S:ins214EPE, S:H69/V70, ORF7b:L11F, and M:D3N. Using the combination of results for each of these markers, samples could be designated as belonging to sublineages within BA.1, BA.2, BA.4, or BA.5. The analytical sensitivity of these markers ranged from 132 to 2229 copies/mL and in-laboratory accuracy was 98.9–100%. A 97.3% agreement using 12,592 specimens was demonstrated for the assays compared to genome sequencing. The use of these assays, combined with genome sequencing, facilitated the surveillance of SARS-CoV-2 lineages throughout a BA.5-dominated period.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada; University of Alberta, Department of Laboratory Medicine and Pathology, Edmonton, Canada (GRID:grid.17089.37)
2 Public Health Laboratory, Alberta Precision Laboratories, Calgary, Canada (GRID:grid.17089.37)
3 Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada (GRID:grid.17089.37); University of Alberta, Department of Laboratory Medicine and Pathology, Edmonton, Canada (GRID:grid.17089.37); University of Alberta, Li Ka Shing Institute of Virology, Edmonton, Canada (GRID:grid.17089.37)
4 Public Health Laboratory, Alberta Precision Laboratories, Calgary, Canada (GRID:grid.17089.37); University of Calgary, Department of Pathology and Laboratory Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
5 Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada (GRID:grid.22072.35)
6 Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada (GRID:grid.22072.35); Public Health Agency of Canada, National Microbiology Laboratory, Edmonton, Canada (GRID:grid.415368.d) (ISNI:0000 0001 0805 4386)
7 Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada (GRID:grid.415368.d)
8 Public Health Laboratory, Alberta Precision Laboratories, Calgary, Canada (GRID:grid.415368.d)
9 University of Alberta, Department of Laboratory Medicine and Pathology, Edmonton, Canada (GRID:grid.17089.37); Public Health Laboratory, Alberta Precision Laboratories, Calgary, Canada (GRID:grid.17089.37); University of Calgary, Division of Infectious Diseases, Department of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
10 Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada (GRID:grid.22072.35); University of Alberta, Li Ka Shing Institute of Virology, Edmonton, Canada (GRID:grid.17089.37); University of Alberta, Department of Medical Microbiology and Immunology, Edmonton, Canada (GRID:grid.17089.37)